---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017836"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:35:29.162747+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio Q3 2022 net loss $19.0M ($0.18/sh); cash $92.4M; MB-106 trial advances

## Summary
- Cash and equivalents $92.4M at Sep 30, 2022, down $16.0M from June 30, $110.6M at Dec 31, 2021.
- Net loss attributable to common stockholders $19.0M ($0.18/sh) vs $17.0M ($0.19/sh) in Q3 2021.
- First patient treated in Mustang-sponsored multicenter Phase 1/2 trial for MB-106 (CD20 CAR T) in B-NHL and CLL.
- Fred Hutch trial: 96% ORR, 75% CR in 28 patients; 12 patients CR >12 months; no Grade ≥3 CRS or ICANS.
- MB-106 granted FDA Orphan Drug Designation for Waldenstrom macroglobulinemia; early Phase 1 results expected Dec 2022.

## SEC filing metadata
- accession: 0001558370-22-017836
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000155837022017836/0001558370-22-017836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000155837022017836/tmb-20221114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017836
- JSON: https://secwatch.observer/filing/0001558370-22-017836.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017836.txt

## Key facts
- Earnings Releases
  MUSTANG BIO, INC. reported the third quarter ended September 30, 2022 results: net income $19.0 million, or $0.18 per share, EPS $0.18 per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: $19.0 million, or $0.18 per share
  - EPS: $0.18 per share
  - Result: reported results
  source text: Net loss attributable to common stockholders was $19.0 million, or $0.18 per share, for the third quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680048/000155837022017836/0001558370-22-017836-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.